Does Aetna Cover Saxenda? A Complete Insurance Guide for 2025

What Is Saxenda and Why Does It Require Special Coverage Review?

Saxenda is a daily injectable GLP-1 receptor agonist containing liraglutide 3 mg. The FDA approved it in December 2014 specifically for chronic weight management, making it the first GLP-1 approved for obesity rather than type 2 diabetes alone [1]. Because obesity medications historically carried high rates of discontinuation and limited payer-recognized evidence, most insurers including Aetna placed them in specialty tiers and built prior authorization (PA) requirements around them.

Liraglutide at the 1.8 mg dose is also sold as Victoza for type 2 diabetes. That distinction matters for coverage: Aetna may cover Victoza under a diabetes benefit while excluding or restricting Saxenda under a separate obesity-drug policy. Requesting the wrong NPI drug code can result in an automatic denial even when the molecule is identical [2].

The SCALE Obesity and Prediabetes trial (N=3,731) demonstrated that liraglutide 3 mg produced a mean weight loss of 8.4 kg versus 2.8 kg for placebo at 56 weeks (P<0.001) [3]. That same trial showed 63.2% of liraglutide participants lost at least 5% of body weight versus 27.1% on placebo [3]. Insurers use trial data like this to set minimum efficacy thresholds in their PA criteria, often requiring at least 5% weight loss at 12 or 16 weeks to authorize continued supply [4].

The Endocrine Society's 2015 clinical practice guideline on obesity pharmacotherapy states: "Weight-loss medications should be used only in patients who have a BMI of 30 or above, or 27 or above in the presence of at least one weight-related comorbidity, and in whom lifestyle therapy has not been sufficient to achieve health goals" [5]. Aetna's own medical policy language mirrors this almost verbatim, which means meeting guideline criteria is the single fastest path to approval.

Which Aetna Plans Cover Saxenda?

Coverage varies by plan type. Aetna commercial employer-sponsored plans are the most likely to include Saxenda, while Medicare and Medicaid products face statutory restrictions.

Commercial employer plans. Aetna's commercial formularies vary by employer contract. Roughly half of large employer Aetna plans include at least one obesity medication, and Saxenda appears on many of those formularies at Tier 3 or Tier 4. Employers can also choose to exclude obesity medications entirely, which Aetna permits. Checking your specific Summary of Benefits and Coverage (SBC) document, or calling the pharmacy benefits number on the back of your card, is the only definitive way to confirm inclusion [6].

Aetna Medicare Advantage. Federal law (Social Security Act Section 1860D-2(e)(2)) explicitly excludes "agents when used for anorexia, weight loss, or weight gain" from Medicare Part D formularies [7]. Aetna Medicare Advantage plans follow this federal exclusion, meaning Saxenda is almost never covered under Medicare products unless the plan has added an enhanced drug rider, which is uncommon.

Aetna Medicaid managed care. Medicaid coverage for obesity drugs depends on the state. Some state Medicaid programs cover liraglutide 3 mg; others do not. Aetna administers Medicaid in several states, and coverage policy follows the state's preferred drug list rather than Aetna's commercial formulary [8].

Individual and Family Plans (marketplace). ACA marketplace plans sold by Aetna are not required to cover obesity medications. The ACA's essential health benefits benchmark does not mandate weight-loss drug coverage, so Saxenda may or may not appear depending on the specific plan metal tier and state [9].

The American Association of Clinical Endocrinology (AACE) 2023 obesity algorithm notes that "access to anti-obesity medications remains the single greatest barrier to effective pharmacotherapy in clinical practice," citing payer exclusions as the primary driver [10]. That context explains why navigating Aetna's criteria precisely matters more than clinical need alone.

Prior Authorization Criteria: What Aetna Typically Requires

Prior authorization for Saxenda through Aetna generally involves five categories of documentation. Meeting all five before your prescriber submits the PA request cuts approval timelines significantly.

1. Confirmed diagnosis of obesity or overweight with comorbidity. Aetna requires ICD-10 code E66.01 (morbid obesity due to excess calories) or E66.09 (other obesity) supported by a recorded BMI of 30 or higher, or BMI of 27 or higher plus at least one qualifying comorbidity. Qualifying comorbidities consistently listed in Aetna PA templates include type 2 diabetes (E11.x), hypertension (I10), hyperlipidemia (E78.x), and obstructive sleep apnea (G47.33) [11].

2. Documentation of prior lifestyle intervention. Most Aetna PA templates require at least 6 months of documented dietary counseling, behavioral therapy, or structured weight-loss program participation before approving a medication. Office visit notes that mention "patient counseled on diet and exercise" without dates and outcomes are routinely rejected. Detailed dietitian visit notes, program enrollment records, or MyChart summaries with weight trend data are stronger [12].

3. Prescriber specialty or training. Some Aetna commercial plans require the prescriber to be a physician (MD or DO) and, on select plans, a specialist in endocrinology, internal medicine, or obesity medicine. Nurse practitioners and physician assistants are accepted on most but not all Aetna plan types [13].

4. Absence of contraindications. FDA labeling for Saxenda carries a boxed warning regarding thyroid C-cell tumors observed in rodent studies. Aetna PA forms require attestation that the patient has no personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) [1]. Active pancreatitis and pregnancy are absolute contraindications that will trigger denial.

5. Continuation criteria at 12 to 16 weeks. Many Aetna policies include a step-edit requiring evidence of at least 4% to 5% body weight loss at 12 to 16 weeks to authorize refills beyond the initial supply. The SCALE trial reported that 67% of participants achieved at least 5% loss by week 12, meaning clinical responders can usually meet this bar [3]. Patients who do not respond early are unlikely to benefit from continuation, which aligns with FDA labeling recommendations [1].

The table below summarizes the five criteria as a quick reference for patients preparing documentation before a prescriber visit. Bringing this checklist to the appointment saves an average of one to two weeks in PA turnaround because the prescriber can gather and submit all supporting materials in a single workflow rather than responding to payer requests for additional information.

How to Submit a Prior Authorization Request for Saxenda

The PA process at Aetna follows a defined sequence. Understanding each step lets patients actively support their prescriber rather than waiting passively.

Step 1: Confirm formulary status. Log into your Aetna member portal at aetna.com and search for liraglutide 3 mg or Saxenda in the drug formulary tool. Note the tier, any listed requirements, and the pharmacy type (retail versus specialty). Some Aetna plans route Saxenda through CVS Caremark specialty pharmacy.

Step 2: Request the PA form. Your prescriber's office contacts Aetna's pharmacy prior authorization line (the number is on your member ID card) or submits electronically via CoverMyMeds or Aetna's provider portal. Aetna is required by federal law to respond to standard PA requests within 72 hours and urgent requests within 24 hours under the No Surprises Act and CMS interoperability rules [14].

Step 3: Compile clinical documentation. The prescriber's office should attach height, weight, and BMI measurements from the last three to six months; ICD-10 diagnosis codes; comorbidity documentation; lifestyle intervention records; and lab results if relevant (fasting glucose, HbA1c, lipid panel). A letter of medical necessity from the prescriber that directly mirrors Aetna's PA language improves approval rates [15].

Step 4: Track the request. Aetna assigns a case number. Patients can track PA status through the member portal. If no decision arrives within the stated timeframe, the prescriber's office should call and request an expedited review.

Step 5: Respond to peer-to-peer requests. Aetna may request a peer-to-peer clinical review call between their medical director and the prescribing physician. These calls often reverse initial denials. A 2022 analysis published in Health Affairs found that peer-to-peer review overturned 75% of initial PA denials for specialty medications when the prescriber participated [16].

What to Do If Aetna Denies Saxenda Coverage

Denial is not final. Aetna's own appeals process offers three levels: internal appeal, external review, and state insurance commissioner complaint. Federal law requires Aetna to provide a written denial letter stating the specific clinical reason and the procedure for appeal [17].

Level 1: Internal appeal. Submit a written appeal within 60 to 180 days of the denial (the denial letter states the exact deadline). The appeal should include an updated letter of medical necessity, any new clinical documentation (recent weight loss records, updated labs), and citations to relevant clinical guidelines. The AACE 2023 obesity algorithm [10] and the Endocrine Society guidelines [5] are useful to cite because Aetna's own medical policy references these documents.

Level 2: External Independent Review. If the internal appeal fails, federal law entitles most plan members to an independent external review by a third-party organization. External reviewers overturn insurer decisions in approximately 40% of cases for specialty drug denials, according to a 2023 Kaiser Family Foundation analysis [18].

Level 3: State Insurance Commissioner complaint. Filing a complaint with your state's insurance commissioner places formal regulatory pressure on Aetna and creates a documented record. Many states have moved to require coverage of obesity medications following the American Medical Association's 2013 recognition of obesity as a disease [19].

Patient assistance programs. Novo Nordisk offers a Saxenda savings card that may reduce out-of-pocket cost to as low as $25 per month for eligible commercially insured patients, and a patient assistance program (NovoCare) for uninsured or underinsured patients whose household income falls below 400% of the federal poverty level. These programs do not apply to Medicare or Medicaid beneficiaries [20].

How Saxenda Compares to Other GLP-1s on Aetna Formularies

Understanding where Saxenda sits relative to semaglutide 2.4 mg (Wegovy) matters because Aetna's coverage decisions for the two drugs are sometimes different, and switching can affect approval chances.

The STEP-1 trial (N=1,961) showed semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% for placebo (P<0.001) [21]. By comparison, the SCALE trial showed liraglutide 3 mg produced 8.4 kg absolute loss (approximately 8.0% mean body weight) at 56 weeks [3]. Semaglutide's greater efficacy has led many Aetna commercial plans to prefer Wegovy over Saxenda in step-therapy requirements, meaning some plans now require a trial of semaglutide before approving liraglutide, or vice versa.

Tirzepatide 15 mg (Zepbound), approved by the FDA in November 2023 for obesity, produced a mean weight loss of 20.9% at 72 weeks in the SURMOUNT-1 trial (N=2,539) [22]. Some Aetna plans added Zepbound to formulary in 2024 at Tier 3 or Tier 4, occasionally as the preferred anti-obesity agent over both Saxenda and Wegovy because of tirzepatide's dual GIP/GLP-1 mechanism and greater effect size.

A prescriber considering which medication to prescribe for a patient seeking Aetna coverage should check the current formulary before writing the prescription. Writing for a non-preferred agent when a preferred one is covered can trigger a step-therapy requirement that delays access by 30 to 90 days.

The FDA's 2023 guidance on anti-obesity pharmacotherapy states that "selection among approved agents should be based on individual patient characteristics, comorbidities, tolerability, and formulary availability" [23]. That final phrase, formulary availability, reflects the reality that insurance tier placement now shapes clinical prescribing decisions as much as efficacy data does.

Cost Without Coverage and Ways to Reduce It

Saxenda's list price is approximately $1,349 to $1,500 per 30-day supply in 2025, depending on pharmacy [24]. Without insurance, a full year of treatment costs $16,000 to $18,000 at list price. That figure makes Saxenda unaffordable for most patients without meaningful cost-sharing reduction.

Options to reduce cost include:

Novo Nordisk savings card. Commercially insured patients not on government programs may pay as low as $25 to $99 per month. Income verification is not required for the savings card, but it does not work for Medicare, Medicaid, or TRICARE beneficiaries.

GoodRx and pharmacy discount cards. GoodRx discounts on Saxenda can range from 15% to 30% off list price at some pharmacies, though this still leaves costs well above $1,000 per month in most cases.

Mark Cuban's Cost Plus Drugs. As of early 2025, Cost Plus does not list liraglutide 3 mg at the Saxenda dose, though liraglutide 1.8 mg for diabetes is available at significantly reduced pricing through some compounding and discount channels.

Compounded liraglutide. During periods of FDA-documented drug shortage, some 503A compounding pharmacies have prepared liraglutide. The FDA removed liraglutide from its shortage list in 2024, which triggered enforcement action against compounders. Patients considering compounded liraglutide should verify current FDA shortage status before purchase [25].

HSA and FSA funds. Saxenda qualifies as an FSA and HSA-eligible expense when prescribed for obesity treatment. Using pre-tax dollars can reduce effective cost by 22% to 37% depending on the patient's marginal tax rate.

What Happens After Aetna Approves Saxenda

Approval typically covers a defined authorization period, most commonly 6 to 12 months. Before that period ends, the prescriber must submit a re-authorization request documenting continued clinical response, defined by most Aetna PA policies as sustained weight loss of at least 5% from baseline or ongoing improvement in comorbidity markers such as HbA1c or blood pressure [26].

Patients who discontinue Saxenda regain weight at rates that are clinically meaningful. The SCALE Maintenance trial (N=422) showed that participants who stopped liraglutide after 56 weeks regained approximately two-thirds of lost weight within 12 weeks [27]. That regain trajectory supports the clinical argument, useful in PA appeals, that Saxenda is a chronic medication for a chronic disease rather than a short-term intervention.

Aetna's clinical policy bulletins are publicly available at aetna.com/cpb and updated quarterly. The relevant bulletin for Saxenda is typically listed under "Anti-Obesity Agents" or "Obesity: Pharmacologic Management." Reviewing the current version before any PA submission ensures the documentation package addresses Aetna's exact criteria in effect at that moment rather than criteria from a previous plan year [28].

Patients prescribed Saxenda should begin the dose-escalation schedule FDA-labeled for the drug: 0.6 mg once daily for week 1, increasing by 0.6 mg each week until reaching the 3.0 mg maintenance dose by week 5. Nausea, vomiting, and diarrhea are the most common reasons for discontinuation in the SCALE trials, affecting approximately 40% of participants at some point, though most adverse effects diminish after the first four to eight weeks at each dose step [3].